On September 30, Valerio Therapeutics, a Paris-based, clinical-stage biotechnology company, announced its acquisition of Emglev Therapeutics.
Founded in 2023, Emglev is a biotechnology company that was established as a spin-off of Institut Curie and aims to develop immunotherapies to address unmet medical needs in oncology. It is a single-domain antibody-based therapeutics company. It is headquartered in Paris, France.
Valerio Therapeutics is focused on developing innovative oncology drugs targeting tumor DNA-binding functions through unique mechanisms of action in the sought-after field of DNA Damage Response. The company is focused on bringing early-stage first-in-class or disruptive compounds from translational research to clinical proof-of-concept, a value-creating inflection point appealing to potential partners.
This transaction established Valour Bio, which will be a subsidiary of Valerio Therapeutics. The transaction was completed on September 29, 2024, enabling the acquisition of Emglev’s unique proprietary platform of fully synthetic single domain antibodies.
The acquisition is structured through a sale of shares paid in cash and a contribution in kind of Emglev shares against Valour Bio shares. As a result, shareholders of Emglev became shareholders of Valour Bio.
According to data captured in the LevinPro HC database, this acquisition represents the 109th Biotechnology transaction of 2024. Between January 1, 2023, and September 25, 2023, there were 117 Biotechnology acquisitions reported.
